CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 607 enrolled
Drug / intervention
MP29-02 +3 moredrug
Likely dose
MP29-02 548 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00660517
NCT00660517Phase 3Completed
CompareCT.gov

Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

Meda Pharmaceuticals·interventional·Posted Apr 17, 2008·Updated Jul 27, 2012

In Brief

A Phase 3 clinical trial evaluating MP29-02, azelastine Hcl, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 607 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 17, 2008
Enrollment StartDec 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.2 years ago

Interventions

MP29-02drug

azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day

azelastine Hcldrug

azelastine Hcl nasal spray one spray per nostril two times a day

fluticasone propionatedrug

fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day

placebodrug

placebo nasal spray one spray per nostril two times a day